J. Huang

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases.

David J. Straus, J. Huang, Marcia A. Testa et al. · Journal of Clinical Oncology · 1998 · 161 citations

Medicine, Oncology, Pharmacology +16

Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants.

C. S. Rabkin, Marcia A. Testa, J. Huang et al. · PubMed · 1999 · 63 citations

Pharmacy, Infectious Diseases, Oncology +13

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

Ranjana H. Advani, Nancy L. Bartlett, Sonali M. Smith et al. · Hematological Oncology · 2019 · 30 citations

Medicine, Immunology, Oncology +17

Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor‐based regimen: week 24 phase 3 results from VIKING‐3

Garrett Nichols, Anthony Mills, Robert Grossberg et al. · Journal of the International AIDS Society · 2012 · 23 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17